Search Result

Isoforms Recommended:	PPARα

Results for "

PPAR-α

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (148) Akt (2) Amyloid-β (2) Antibiotic (2) Apoptosis (5) Autophagy (10) Bacterial (8) Calcium Channel (2) Cannabinoid Receptor (1) COX (7) Cytochrome P450 (10) Drug Intermediate (1) Endogenous Metabolite (12) Epoxide Hydrolase (3) ERK (4) Fatty Acid Synthase (FASN) (3) Ferroptosis (1) FLAP (2) Free Fatty Acid Receptor (2) Fungal (3) Glycosidase (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) iGluR (2) IKK (1) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (14) JNK (2) Keap1-Nrf2 (1) Leukotriene Receptor (2) NF-κB (5) NO Synthase (2) Orthopoxvirus (1) p38 MAPK (2) PARP (2) Phosphatase (2) Phosphodiesterase (PDE) (2) PKA (2) RAR/RXR (1) Reactive Oxygen Species (2) SOD (3) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TGF-beta/Smad (2)
By Research Areas:	Cancer (37) Cardiovascular Disease (43) Infection (9) Inflammation/Immunology (40) Metabolic Disease (105) Neurological Disease (4)
Oligonucleotides:	Cholesterol (1)

163

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: PPAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143239

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

HY-139177

PPARα agonist 2	PPAR	Cardiovascular Disease
PPARα agonist 2 (compound 4u) is a potent and selective *PPARα* agonist with an EC₅₀ of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .

HY-159146

PPARα agonist 4	PPAR STING Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
PPARα agonist 4 (compound BH400) is a *PPARα* agonist (EC₅₀= 1.2 μM). PPARα agonist 4 also inhibits STING (IC₅₀: 8.1 μM). PPARα agonist 4 reduces the CoCl₂-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS .

HY-163862

PPARα agonist 3	PPAR Reactive Oxygen Species	Inflammation/Immunology
PPARα agonist 3 (Compound A229) is a *PPARα* agonist (EC₅₀: 590 nM). PPARα agonist 3 inhibits TBHP or 4-HNE (HY-113466)-induced production of ROS .

HY-173217

PPARα agonist 5	PPAR Phosphatase	Cardiovascular Disease Metabolic Disease
PPARα agonist 5 is an orally available, selective partial agonist of *PPARα* (EC₅₀: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .

HY-146733

PPARα agonist 1	PPAR	Inflammation/Immunology
PPARα agonist 1 is a potent and full hPPARα agonist .

HY-U00068

PPARα-MO-1	PPAR	Metabolic Disease
PPARα-MO-1 is a potent *PPARα* modulator extracted from patent WO/2004/110982A1, formula I.

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/γ agonist 4 (compound 14) is a potent *PPARα* and PPARδ agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/γ agonist 4 shows anti-inflammatory effects .

HY-148922

PPARα/γ agonist 2	PPAR	Metabolic Disease
PPARα/γ agonist 2 is an orally active *PPARα* full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC₅₀ values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .

HY-168485

PPARα/δ agonist 3	PPAR	Metabolic Disease
PPARα/δ agonist 3 (Compound 8) is the orally active agonist for *PPAR, that activates PPARα, PPARδ and PPARγ with EC₅₀s of 5.6, 3.4 and 1278 nM, respectively. PPAR*α/δ agonist 3 exhibits anticholestatic activity in mouse ANIT- or CDCA (HY-76847)-induced cholestatic liver disease models .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-162578

PPARα/γ agonist 4	PPAR	Metabolic Disease
PPARα/γ agonist 4 (Compound (S)-7) is an orally active dual potent agonist of *PPARα* and PPARγ, with EC₅₀ values of 0.061 μM and 1.42 μM respectively. PPARα/γ agonist 4 acts through an insulin-independent mechanism and exhibits mitochondrial pyruvate carrier inhibition and anti-diabetic properties. PPARα/γ agonist 4 is expected to be used in research for dyslipidemic type 2 diabetes .

HY-162122

PPARα/γ agonist 3	PPAR	Inflammation/Immunology
PPARα/γ agonist 3 (Compound 4) is a dual agonist of PPARα/γ. PPARα/γ agonist 3 has anti-inflammatory activity, significantly reducing inflammatory markers such as IL-6 and MCP-1 on THP-1 macrophages through NF-κB activation. PPARα/γ agonist 3 can be used in the study of metabolic syndrome and metabolic dysfunction-related fatty liver disease (MAFLD) .

HY-167950

PPARα/γ agonist 5	PPAR	Metabolic Disease
PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC₅₀ of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy .

HY-119197

PPARα/γ/δ agonist 1	PPAR	Metabolic Disease
PPARα/γ/δ agonist 1 (Compound 2) is a potent PPARα/γ/δ agonist, with an IC₅₀ of 70 nM for PPARγ. PPARα/γ/δ agonist 1 can be used for the research of type 2 diabetes .

HY-117131

ZINC17167211	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
ZINC17167211 is a potent *PPAR-α* agonist (EC₅₀=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases .

HY-114700

ZINC08438472	PPAR	Metabolic Disease Inflammation/Immunology
ZINC08438472 is a potent and selective peroxisome proliferator activated receptors-α (PPAR-α) agonist with an EC₅₀ value of 12.1 nM. ZINC08438472 is promising for research of diabetes, hyperlipidaemia and inflammatory disorders .

HY-117196

GW 9578	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective *PPARα* agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-107542

Oleoylethanolamide 2 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N1426

Raspberry ketone 1 Publications Verification Frambione; 4-(4-Hydroxyphenyl)-2-butanone	PPAR	Cardiovascular Disease Metabolic Disease
Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows *PPAR-α* agonistic activity.

HY-156977

Sitofibrate	PPAR	Cardiovascular Disease
Sitofibrate is a Clofibrate (HY-B0287) derivative. Sitofibrate is aperoxisome proliferator activated receptor-α (PPAR-α) agonist. Sitofibrate is an antihyperlipidemic agent .

HY-107542S2

Oleoylethanolamide-d2 N-Oleoylethanolamide-d₂; Oleamide MEA-d₂; Oleic acid monoethanolamide-d₂	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S

Oleoylethanolamide-d4 N-Oleoylethanolamide-d₄; Oleamide MEA-d₄; Oleic acid monoethanolamide-d₄	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N1426R

Raspberry ketone (Standard)	PPAR	Cardiovascular Disease Metabolic Disease
Raspberry ketone (Standard) is the analytical standard of Raspberry ketone. This product is intended for research and analytical applications. Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows PPAR-α agonistic activity.

HY-114263

NXT629 3 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-B0258

Gemfibrozil 1 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of *PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450* isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258R

Gemfibrozil (Standard) 1 Publications Verification CI-719 (Standard)	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of *PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450* isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258S1

Gemfibrozil-d6-1 CI-719-d₆-1	Cytochrome P450 PPAR Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of *PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450* isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-U00014

AVE-8134	PPAR	Metabolic Disease
AVE-8134 is a potent *PPARα* agonist, with EC₅₀ values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-16995

Pirinixic acid 15+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of *PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα* and PPARγ, and 5.0 μM, 60 μM, 35 μM for human *PPARα, PPARγ and PPAR*δ, respectively.

HY-13861

GW7647 15+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-50665

LY518674 LY-674	PPAR	Metabolic Disease
LY518674 is a potent, selective *PPARα* agonist, with an EC₅₀ of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis .

HY-B0287

Clofibrate 2 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-10678

BMS-687453 2 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective *PPARα* agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human *PPARα* and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-15372

GW6471 50+ Cited Publications	PPAR	Cancer
GW6471 is a potent *PPARα* antagonist.

HY-17618A

Rac-Pemafibrate Rac-K13675	PPAR	Inflammation/Immunology
Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates *PPARα* activity, with EC₅₀s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.

HY-N0234R

Bavachinin (Standard)	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-121448

GW409544	PPAR	Cardiovascular Disease Metabolic Disease
GW409544 is a potent *PPARα* and PPARγ activator, with EC₅₀ values of 2.3 nM and 0.28 nM for *PPARα* and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases .

HY-17618

Pemafibrate 5+ Cited Publications (R)-K-13675	PPAR	Cardiovascular Disease Inflammation/Immunology
Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-106278

GW 590735	PPAR	Metabolic Disease
GW 590735 is a potent and selective *PPARα* agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-B0287S

Clofibrate-d4	PPAR	Metabolic Disease
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-108571

CP-775146	PPAR	Metabolic Disease
CP-775146 is a selective *PPARα* agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual-target PPARα/γ agonist with an EC₅₀ of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .

HY-129683

AM3102	PPAR	Metabolic Disease
AM3102 is an oleoylethanolamide (OEA) analog. AM3102 is an endogenous high-affinity PPAR-alpha agonist. AM3102 resists enzymatic hydrolysis, activates PPAR-alpha with high potency in vitro, and persistently reduces feeding when administered in vivo either parenterally or orally .

HY-B0287R

Clofibrate (Standard) 2 Publications Verification	PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-172413

Amezalpat	PPAR	Cancer
Amezalpat is the antagonist for *PPARα* with IC₅₀ of 58 nM. Amezalpat exhibits antineoplastic activity .

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107542

Oleoylethanolamide 2 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Cardiovascular Disease Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite PPAR
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N1426

Raspberry ketone 1 Publications Verification Frambione; 4-(4-Hydroxyphenyl)-2-butanone	Cardiovascular Disease Structural Classification Monophenols Classification of Application Fields Rubus idaeus Linn. Source classification Rosaceae Phenols Plants Disease Research Fields	PPAR
Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows *PPAR-α* agonistic activity.

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N0458

Pedunculoside 1 Publications Verification	Aquifoliaceae Triterpenes Structural Classification Classification of Application Fields Terpenoids Ilex rotunda Thunb. Source classification Metabolic Disease Plants Disease Research Fields	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-N0783

Eupatilin 5+ Cited Publications	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Flavones Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite PPAR
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N1426R

Raspberry ketone (Standard)	Structural Classification Monophenols Rubus idaeus Linn. Source classification Rosaceae Phenols Plants	PPAR
Raspberry ketone (Standard) is the analytical standard of Raspberry ketone. This product is intended for research and analytical applications. Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows PPAR-α agonistic activity.

HY-N0234R

Bavachinin (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Isoflavones	PPAR
Wistin, isolated from Caragana sinica roots, is a *PPARα* and PPARγ agonist .

HY-N0458R

Pedunculoside (Standard)	Aquifoliaceae Triterpenes Structural Classification Terpenoids Ilex rotunda Thunb. Source classification Plants	Fatty Acid Synthase (FASN)
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-N0014

Icariin Maximum Cited Publications 17 Publications Verification Ieariline	Cardiovascular Disease Flavonols Structural Classification Classification of Application Fields Anti-aging Source classification Plants Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a *PPARα* activator.

HY-N0783R

Eupatilin (Standard)	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Source classification Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Fungal PPAR
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a *PPARα* agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-N0014R

Icariin (Standard) Ieariline (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Plants Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin (Standard) is the analytical standard of Icariin. This product is intended for research and analytical applications. Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a *PPARα* activator.

HY-N1990

Gypenoside XLIX	Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino Disease Research Fields	PPAR
Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-N11722

Panduratin A	Structural Classification Source classification Phenols Polyphenols Boesenbergia rotunda Plants Zingiberaceae	PPAR Apoptosis Bacterial
Panduratin A, a natural chalcone compound, is a *PPAR-α/δ* activator. Panduratin A induces apoptosis, and promotes cell cycle arrest at G0/G1 phase in multiple hematologic malignant cell lines. Panduratin A has anticancer, antioxidant, anti-inflammatory, antibacterial, and antibiofilm activities .

HY-N1967

Dihydrocurcumin	Zingiber officinale Roscoe Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Zingiberaceae	Fatty Acid Synthase (FASN)
Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways .

HY-N6869

Dehydroabietic acid	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N0368R

Linalool (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Terpenoids Source classification Amberboa moschata (L.) DC. Umbelliferae Plants Endogenous metabolite Disease Research Fields	iGluR Apoptosis Endogenous Metabolite
Linalool (Standard) is the analytical standard of Linalool. This product is intended for research and analytical applications. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity .Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome .

HY-N4103

Fucosterol	Structural Classification other families Classification of Application Fields Source classification Metabolic Disease Plants Endogenous metabolite Disease Research Fields Steroids	PARP Endogenous Metabolite
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of *PPARα* and C/EBPα expression and can be used for anti-obesity agents development research .

HY-N5097

13-Oxo-9E,11E-octadecadienoic acid	Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	PPAR
13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent *PPARα* activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice .

HY-N1029

Norathyriol 1 Publications Verification Mangiferitin	Structural Classification Classification of Application Fields Source classification Mangifera indica Linn. Plants Endogenous metabolite Infection Human Gut Microbiota Metabolites Phenols Polyphenols Inflammation/Immunology Disease Research Fields Anacardiaceae	Glycosidase PPAR
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC₅₀ of 3.12 μM . Norathyriol inhibits *PPARα, PPARβ, and PPARγ with IC₅₀*s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.

HY-N1990R

Gypenoside XLIX (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino	PPAR
Gypenoside XLIX (Standard) is the analytical standard of Gypenoside XLIX. This product is intended for research and analytical applications. Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-121389

Hexadecanamide Palmitamide	Infection Structural Classification Alkaloids Cannabis sativa L Classification of Application Fields Other Alkaloids Source classification Plants Moraceae Inflammation/Immunology Disease Research Fields	Bacterial NF-κB PPAR
Hexadecanamide (Palmitamide), a fatty acid amide, has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide alleviate S. aureus-caused mastitis by depressing inflammatory response and maintaining blood-milk barrier integrity. Hexadecanamide depresses S. aureus-induced activation of the NF-κB pathway in mouse mammary epithelial cells (MMECs). Hexadecanamide activates *PPARα*. Hexadecanamide enhances sperm motility in vitro .

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Source classification Diterpenoids Plants	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-W107616

3,7,11,15-Tetramethyl-2-hexadecen-1-ol	Structural Classification Natural Products Rudbeckia laciniata L. Source classification Plants Compositae	Endogenous Metabolite
3,7,11,15-Tetramethyl-2-hexadecen-1-ol can be used to synthesize vitamin E and vitamin E's precursor vitamin K1. 3,7,11,15-Tetramethyl-2-hexadecen-1-ol regulates transcription in cells through the transcription factor PPAR-alpha and the retinoid X receptor (RXR)43 .

HY-N4103R

Fucosterol (Standard)	Structural Classification other families Classification of Application Fields Source classification Metabolic Disease Plants Endogenous metabolite Disease Research Fields Steroids	PARP Endogenous Metabolite
Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of *PPARα* and C/EBPα expression and can be used for anti-obesity agents development research .

HY-N2118

Bilobetin 2 Publications Verification	Structural Classification Flavonoids Ginkgoaceae Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Biflavones Ginkgo biloba Disease Research Fields	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of *PPARα* accompanied by elevated cAMP level and PKA activity .

HY-N2118R

Bilobetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Source classification Phenols Polyphenols Plants Biflavones Ginkgo biloba	PPAR PKA Akt p38 MAPK ERK
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-N0515

Ophiopogonin D	Ophiopogon japonicus (L. f.) Ker-Gawl. Cardiovascular Disease Structural Classification Liliaceae Classification of Application Fields Source classification Plants Disease Research Fields Steroids	PPAR NF-κB Calcium Channel
Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-113038AR

α-Hydroxyglutaric acid (disodium) (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Histone Demethylase Endogenous Metabolite
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-N0515R

Ophiopogonin D (Standard)	Ophiopogon japonicus (L. f.) Ker-Gawl. Structural Classification Liliaceae Source classification Plants Steroids	PPAR NF-κB Calcium Channel
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

Species:	Human (1) Mouse (1)
Tag:	His (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7996

	PPAR alpha Protein, Human (His) 1 Publications Verification PPARA, PPAR-α	Human	E. coli
	PPAR alpha Protein, human (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

HY-P702843

	PPAR alpha Protein, Mouse (His) PPARA, PPAR-α	Mouse	E. coli
	PPAR alpha Protein, Mouse (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of *PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450* isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-N6807S

Elemicin-d3
Elemicin-d₃ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-16578S

GW9662-d5
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively[1][2].

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-B0760S1

Fenofibric acid-13C8
Fenofibric acid- ¹³C₈ (FNF acid- ¹³C₈) is ¹³C labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-N0368S

Linalool-d3
Linalool-d₃ is the deuterium labeled Linalool[1]. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity[2].Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome[3].

HY-121538S

CUDA-d11
CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-B0760S

Fenofibric acid-d6
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-B0760S2

Fenofibric acid-d4
Fenofibric acid-d₄ (FNF acid-d₄) is deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-B1415S

Clofibric acid-d4

Clofibric acid-d₄ is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80871

	PPAR alpha Antibody PPARA; NR1C1; PPAR; Peroxisome proliferator-activated receptor alpha; PPAR-alpha; Nuclear receptor subfamily 1 group C member 1	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	PPAR alpha Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 52 kDa, targeting to PPAR alpha. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-N4103

Fucosterol		Cholesterol
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of *PPARα* and C/EBPα expression and can be used for anti-obesity agents development research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PPAR-α

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products